Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background/aims: Traditional on-site monitoring of clinical trials via frequent site visits and 100% source data verification is cost-consuming, and it still cannot guarantee data quality effectively. Depending on the types and designs of clinical trials, an alternative would be combining several monitoring methods, such as risk-based monitoring and remote monitoring. However, there is insufficient evidence of its effectiveness. This research compared the effectiveness of risk-based monitoring with a remote monitoring system with that of traditional on-site monitoring.

Methods: With a cloud-based remote monitoring system called beagle View, we created a remote risk-based monitoring methodology that focused only on critical data and processes. We selected a randomized controlled trial conducted at Tohoku University Hospital and randomly sampled 11 subjects whose case report forms had already been reviewed by data managers. Critical data and processes were verified retrospectively by remote risk-based monitoring; later, all data and processes were confirmed by on-site monitoring. We compared the ability of remote risk-based monitoring to detect critical data and process errors with that of on-site monitoring with 100% source data verification, including an examination of clinical trial staff workload and potential cost savings.

Results: Of the total data points (n = 5617), 19.7% (n = 1105, 95% confidence interval = 18.7-20.7) were identified as critical. The error rates of critical data detected by on-site monitoring, remote risk-based monitoring, and data review by data managers were 7.6% (n = 84, 95% CI = 6.2-9.3), 7.6% (n = 84, 95% confidence interval = 6.2-9.3), and 3.9% (n = 43, 95% confidence interval = 2.9-5.2), respectively. The total number of critical process errors detected by on-site monitoring was 14. Of these 14, 92.9% (n = 13, 95% confidence interval = 68.5-98.7) and 42.9% (n = 6, 95% confidence interval = 21.4-67.4) of critical process errors were detected by remote risk-based monitoring and data review by data managers, respectively. The mean time clinical trial staff spent dealing with remote risk-based monitoring was 9.9 ± 5.3 (mean ± SD) min per visit per subject. Our calculations show that remote risk-based monitoring saved between 9 and 41 on-site monitoring visits, corresponding to a cost of between US$13,500 and US$61,500 per trial site.

Conclusion: Remote risk-based monitoring was able to detect critical data and process errors as well as on-site monitoring with 100% source data verification, saving travel time and monitoring costs. Remote risk-based monitoring offers an effective alternative to traditional on-site monitoring of clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774520971254DOI Listing

Publication Analysis

Top Keywords

risk-based monitoring
48
remote risk-based
40
on-site monitoring
36
monitoring
27
critical data
20
95% confidence
20
data
17
100% source
16
source data
16
data verification
16

Similar Publications

Introduction: Frequent glycated hemoglobin A1c (HbA1c) monitoring is recommended in individuals with type 2 diabetes mellitus (T2D). We aimed to identify distinct, long-term HbA1c trajectories following a T2D diagnosis and investigate how these glycemic control trajectories were associated with health-related traits and T2D complications.

Research Design And Methods: A cohort of 12,435 unrelated individuals of European ancestry with T2D was extracted from the UK Biobank data linked to primary care records.

View Article and Find Full Text PDF

Background: Intracranial meningiomas are the most common benign central nervous system tumors, often managed with elective surgical resection. While outcomes are generally favorable, postoperative management remains variable, particularly regarding routine Intensive-Care Units (ICU) admission. Given increasing pressure on critical care resources, identifying patients who truly require ICU-level monitoring is essential.

View Article and Find Full Text PDF

From the perspective of interest conflicts, this study investigates the relationship between corporate leverage manipulation and financial risk using a sample of A-share listed real estate firms in China from 2009 to 2023. Employing a two-way fixed effects model, the main findings are as follows: (1) Leverage manipulation significantly increases the level of financial risk among real estate firms; (2) Mechanism analysis reveals a collusion effect between controlling shareholders and management, as well as between external auditors and management, both of which significantly amplify the impact of leverage manipulation on financial risk. These findings support the collusion effect hypothesis and reject the monitoring effect hypothesis; (3) Heterogeneity tests show that the impact of leverage manipulation on financial risk is more pronounced in non-state-owned enterprises, in firms dominated by transactional institutional investors, and in regions with lower reliance on land finance.

View Article and Find Full Text PDF

Purpose: The Naseri Artificial Wetland was created by the discharge of agricultural drainage water, including effluent from the sugarcane development project. The continuous inflow of drainage water from the sugarcane development units has altered the natural regime of the wetland. Considering the high probability of herbicides entering agricultural runoff, this study was conducted to identify atrazine and to assess the health risks of it in this wetland.

View Article and Find Full Text PDF

The worldwide market for over-the-counter (OTC) medications is quickly developing, providing consumers with increased self-medication options while facing substantial regulatory issues due to varied approval procedures, labeling regulations, and safety standards between nations. Despite efforts to standardize regulatory frameworks, differences in component classification, dosage limitations, and risk assessment standards impede producers, healthcare professionals, and lawmakers. This analysis looks at the regulatory environment of over-thecounter pharmaceuticals in major countries, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and regulatory organizations in Asia- Pacific and developing economies, highlighting notable disparities in approval procedures, marketing authorization, and pharmacovigilance.

View Article and Find Full Text PDF